Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis
- Authors:
- Linda Calistri
- Cesare Cordopatri
- Cosimo Nardi
- Elena Gianni
- Fabio Marra
- Stefano Colagrande
-
Affiliations: Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence‑Azienda Ospedaliero‑Universitaria Careggi, I‑50134 Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, I‑50134 Florence, Italy - Published online on: January 16, 2017 https://doi.org/10.3892/mco.2017.1132
- Pages: 389-396
This article is mentioned in:
Abstract
 |
 |
|
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raolul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Verstraete KL, Van der Woude HJ, Hogendoorn PC, De-Deene Y, Kunnen M and Bloem JL: Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: Basic principles and clinical applications. J Magn Reson Imaging. 6:311–321. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnosn MM, Macapiniac HA and Podoloff DA: CT evaluation of the response of gastrointestinal stromal tumors after imatinibmesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 183:1619–1628. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Namkung S, Zech CJ, Helmberger T, Reiser MF and Schoenberg SO: Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: Efficacy for characterization of focal liver lesions. J Magn Reson Imaging. 25:755–765. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Santoro L, Grazioli L, Filippone A, Grassedonio E, Belli G and Colagrande S: Resovist enhanced MR imaging of the liver: Does quantitative assessment help in focal lesion classification and characterization? J Magn Reson Imaging. 30:1012–1020. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
So BJ, Bekaii-Saab T, Bloomston MA and Patel T: Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J Hematol Oncol. 1:182008. View Article : Google Scholar : PubMed/NCBI | |
|
Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V and Borg C: Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: A case report. J Clin Oncol. 29:e330–e332. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V and Belghiti J: Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver int. 31:740–743. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang SX, Byrnes A, Verma S, Pancoast JR and Rixe O: Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: A case report. Target Oncol. 5:59–63. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, Battaglia V, Romano A, Bertoni M, Capria A, et al: Complete response for advanced liver cancer during sorafenib therapy: Case report. BMC Gastroenterol. 11:42011. View Article : Google Scholar : PubMed/NCBI | |
|
Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E and Santoro A: Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib. World J Gastroenterol. 17:2450–2453. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shiba S, Okusaka T, Ikeda M, Saito H and Ichida T: Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 44:1268–1276. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Du J, Qian X and Liu B: Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature. Oncol Lett. 5:381–385. 2013.PubMed/NCBI | |
|
Ozenne V, Paradis V, Pernot S, Casteinau C, Vullierme MP, Bouattour M, Valla D, Farges O and Degos F: Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 22:1106–1110. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G and Bruix J: SHARP Investigators Study Group: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 18:2290–2300. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Villanueva A and Llovet JM: Targeted therapies for hepatocellular carcinoma. Gastroenterology. 140:1410–1426. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Villanueva A and Llovet JM: Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology. 56:2416–2419. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS, Kim BH, Kim BC, Shin A, Kim JS, Hong SH, Hwang JA, Lee JA, Nam S, Lee SH, et al: SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: Whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget. 6:16449–16460. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH and Cheng AL: Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 116:4590–4596. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Huan HB, Lau WY, Xia F, Ma KS and Bie P: Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol. 20:14505–14509. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Xu B, Fu L and Hao XS: Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res. 25:403–409. 2006.PubMed/NCBI | |
|
Novi M, Lauritano EC, Piscaglia AC, Barbaro B, Zocco MA, Pompili M and Gasbarrini A: Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol. 104:1852–1854. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Holalkere NS, Muzikansky A, Horgan K and Sahani DV: Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 13:120–125. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang T, Zhu AX and Sahani DV: Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol. 58:169–177. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mungai F, Pasquinelli F, Mazzoni LN, Virgili G, Ragozzino A, Quaia E, Morana G, Giovagnoni A, Grazioli L and Colagrande S: Diffusion-weighted magnetic resonance imaging in prediction and assessment of chemotherapy outcome in liver metastases. Radiol Med. 119:625–633. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C and Biasco G: Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 12:2312012. View Article : Google Scholar : PubMed/NCBI | |
|
Hagihara A, Teranishi Y, Kawamura E, Fujii H, Iwai S, Morikawa H, Enomoto M, Tamori A and Kawada N: A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. Intern Med. 52:1589–1592. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shiozawa K, Watanabe M, Ikcara T, Matsukiyo Y, Kogame M, Kanayama M, Matsui T, Kikuchi Y, Ishii K, Igarashi Y and Sumino Y: Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report. Oncol Lett. 7:50–52. 2014.PubMed/NCBI | |
|
Sivendran S, Liu Z, Portas LJ Jr, Yu M, Hahn N, Sonpavde G, Oh WK and Galsky MD: Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. Cancer Treat Rev. 38:919–925. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 27:3312–3318. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R and Pazdur R: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 14:95–100. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A and Sundaresan PR: Aphase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 67:751–764. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M and Schmidinger H: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 26:5204–5212. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, Shono M and Ogawa H: Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 54:512–515. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Porto I, Leo A, Miele L, Pompili M, Landolfi R and Crea F: A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol. 7:476–480. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Naib T, Steingart RM and Chen CL: Sorafenib-associated multivessel coronary artery vasospasm. Herz. 36:348–351. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hoshijima M and Chien KR: Mixed signals in heart failure: Cancer rules. J Clin Invest. 109:849–855. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ederhy S, Izzedine H, Massard C, Dufaitre G, Spanp JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, et al: Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 80:369–379. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Force T, Krause DS and Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 7:332–344. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hasinoff BB and Patel D: Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol. 10:1–8. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kamba T and McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 96:1788–1795. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kawabata M, Umemoto N, Shimada Y, Nishimura Y, Zhang B, Kuroyanagi J, Miyabe M and Tanaka T: Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. Toxicol Sci. 143:374–384. 2015. View Article : Google Scholar : PubMed/NCBI |
